Evidence map›Paper›PMID 32509815›Full record

ArticleHepatobiliary surgery and nutrition2020

Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer.

Scott Kizy, Ariella M Altman, Keith M Wirth, Schelomo Marmor, Jane Y C Hui, Todd M Tuttle, Emil Lou, Khalid Amin, Jason W Denbo, Eric H Jensen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatobiliary surgery and nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Scott KizyDivision of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Ariella M AltmanDivision of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Keith M WirthDivision of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Schelomo MarmorDivision of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Jane Y C HuiDivision of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Todd M TuttleDivision of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Emil LouDivision of Hematology and Oncology, Department of Internal Medicine, University of Minnesota, Minneapolis, MN, USA.
Khalid AminDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Jason W DenboDivision of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Eric H JensenDivision of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · US

Funding

Training the Next Generation of Surgeon-Scientists in PancreatologyT32DK108733 · NIDDK · UNIVERSITY OF MINNESOTA · PI Srinath Chinnakotla, MASATO YAMAMOTO · 2017 to 2026
$1.4M
NIDDK NIH HHS T32 DK108733
6 · The paper itself

Abstract

backgroundThe utility of neoadjuvant treatment for resectable pancreas cancer is yet to be determined, but has commonly included chemoradiation. We evaluated outcomes in patients with radiographically resectable pancreatic adenocarcinoma treated with neoadjuvant chemotherapy without chemoradiation.

methodsA retrospective review of patients in our institutional pancreatic cancer registry was performed, which identified 36 patients who received neoadjuvant chemotherapy alone for resectable pancreatic adenocarcinoma between 2012 and 2016.

resultsMedian age at diagnosis was 66.3 years. Chemotherapy regimens included gemcitabine (n=17), gemcitabine/nab-paclitaxel (n=8), or 5-FU/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) (n=11). Surgical resection was performed in 69% of patients (n=25), with an R0 resection rate of 92% (n=23 patients). During chemotherapy, distant disease became apparent in 19% of patients (n=7), while no patients had evidence of local progression. Resection rates were similar between chemotherapy regimens (single agent =59%, multiple agent =79%). Median overall survival for all patients who received neoadjuvant chemotherapy was 30.3 and 34.4 months for those who underwent surgical resection. There was no difference in median survival for patients treated with gemcitabine (31.3 months) or multi-agent chemotherapy (29.7 months).

conclusionsA short course of neoadjuvant chemotherapy without chemoradiation may improve patient selection prior to surgical resection for pancreas cancer. Further, local disease progression did not limit surgical resection in this small series.

Indexed as

chemotherapyneoadjuvant chemotherapyPancreatic adenocarcinomaresectionsurvival

Identifiers

PMID32509815
PMCPMC7262615
OpenAlexW2953135950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.